Adicet Bio Inc (ACET) Stock Price, Quote & News

Company Profile

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 503 9095

Website: www.adicetbio.com

Address:

131 Dartmouth Street, 3rd Floor, Boston, United States

BiotechValues Sep. 15 at 8:04 PM

$ACET wants to show CRR of 40%+ at 12 months in LN population for a win

0 · Reply

BullyMCBullface Sep. 15 at 7:34 PM

$ACET 🙌🏻🙌🏻🙌🏻🙌🏻🙌🏻

0 · Reply

BiotechValues Sep. 15 at 7:26 PM

$ACET no red flags in HCW presentation. CEO discussed moving into pivotal LN study (maybe add SLE too) and startup activities beginning in q4 and final FDA protocol q4. Sounds like they think they have a win coming:

0 · Reply

THSSKS Sep. 15 at 6:07 PM

$ACET bought a small stake here. Don’t let me down

0 · Reply

thebrockettman Sep. 15 at 4:15 PM

$ACET Presentation not till at 3pm et.. hopefully we have some good news to put us back on track. This sell off seems crazy. https://investor.adicetbio.com/news-releases/news-release-details/adicet-bio-participate-fireside-chat-hc-wainwright-28th-annual

0 · Reply

rml360 Sep. 15 at 3:59 PM

$ACET shit did the data leak?

0 · Reply

Peterson28 Sep. 15 at 3:39 PM

$ACET Stop loss hunting

0 · Reply

BioTechChap Sep. 15 at 3:10 PM

$ACET 2 weeks of gain wiped out in 2 hours. They better have a solid story during HCW Conference today

1 · Reply

glaucio Sep. 14 at 4:48 PM

$ACET you’re alive

0 · Reply

danielmaia12 Sep. 9 at 12:02 PM

$ACET Multiple cancer indications give the platform several shots on goal...

0 · Reply

Adicet Bio Transcript: H.C. Wainwright 28th Annual Global Investment Conference

Sep 2, 2026, 4:00 PM EDT - 13 days ago

Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference

2026-09-01T11:15:44.000Z - 14 days ago

Adicet Bio completes last patient visit for analysis of prula-cel in lupus

Sep 1, 2026, 7:00 AM EDT - 15 days ago

Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update

Aug 31, 2026, 5:39 PM EDT - 15 days ago

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

2026-08-27T20:05:40.000Z - 19 days ago

Adicet Bio announces FDA clearance of IND application for ADI-212

Aug 27, 2026, 4:00 PM EDT - 19 days ago

Adicet Bio Announces FDA Clearance of IND Application for ADI-212

Aug 11, 2026, 10:30 AM EDT - 5 weeks ago

Adicet Bio Transcript: Canaccord Genuity's 46th Annual Growth Conference

2026-08-06T10:53:16.000Z - 5 weeks ago

Adicet Bio price target lowered to $90 from $100 at Guggenheim

2026-08-05T20:52:47.000Z - 5 weeks ago

Adicet Bio reports Q2 EPS ($1.99), consensus ($1.64)

Aug 5, 2026, 4:15 PM EDT - 5 weeks ago

Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

Aug 5, 2026, 4:00 PM EDT - 5 weeks ago

Adicet Bio Quarterly report: Q2 2026

Aug 5, 2026, 4:00 PM EDT - 5 weeks ago

Adicet Bio Earnings release: Q2 2026

Aug 1, 2026, 8:00 AM EDT - 6 weeks ago

Adicet Bio Slides: Investor presentation

Jul 21, 2026, 4:00 PM EDT - 1 month ago

Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference

Jun 17, 2026, 5:00 PM EDT - 3 months ago

Adicet Bio Transcript: AGM 2026

Jun 4, 2026, 7:35 AM EDT - 3 months ago

Adicet Bio Transcript: Jefferies Global Healthcare Conference 2026

May 14, 2026, 4:00 PM EDT - 4 months ago

Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference

2026-05-13T20:24:33.000Z - 4 months ago

Adicet Bio reports Q1 EPS ($1.88), consensus ($3.08)

May 13, 2026, 4:01 PM EDT - 4 months ago

Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates

May 13, 2026, 4:00 PM EDT - 4 months ago

Adicet Bio Earnings release: Q1 2026

May 13, 2026, 4:00 PM EDT - 4 months ago

Adicet Bio Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 4 months ago

Adicet Bio Slides: Investor presentation

2026-05-04T20:41:09.000Z - 4 months ago

Adicet Bio assumed with a Buy at Jefferies

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Adicet Bio Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Adicet Bio Proxy statement: Proxy filing

2026-03-23T10:10:51.000Z - 5 months ago

Adicet Bio price target lowered to $27 from $50 at H.C. Wainwright

2026-03-13T11:40:50.000Z - 6 months ago

Adicet Bio price target lowered to $100 from $128 at Guggenheim

2026-03-12T21:20:37.000Z - 6 months ago

Adicet Bio files $250M mixed securities shelf

Mar 12, 2026, 5:00 PM EDT - 6 months ago

Adicet Bio Annual report: Q4 2025

Mar 12, 2026, 5:00 PM EDT - 6 months ago

Adicet Bio Earnings release: Q4 2025

2026-03-12T20:05:37.000Z - 6 months ago

Adicet Bio reports Q4 EPS ($2.94), consensus ($2.99)

Mar 12, 2026, 4:00 PM EDT - 6 months ago

Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

Mar 12, 2026, 8:00 AM EDT - 6 months ago

Adicet Bio Registration statement: Registration Filing

Mar 12, 2026, 7:00 AM EDT - 6 months ago

Adicet Bio Slides: Investor presentation

Jan 30, 2026, 7:00 AM EST - 7 months ago

Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

2026-01-21T11:16:04.000Z - 7 months ago

Adicet Bio price target adjusted to $50 from $9 at H.C. Wainwright

Jan 7, 2026, 7:00 AM EST - 8 months ago

Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones

2026-01-06T11:26:03.000Z - 8 months ago

Adicet Bio price target lowered to $18 from $128 at Canaccord

2025-12-30T00:55:17.000Z - 8 months ago

Adicet Bio trading halted, news pending

Dec 26, 2025, 8:30 AM EST - 8 months ago

Adicet Bio Announces Reverse Stock Split

Nov 17, 2025, 7:00 AM EST - 10 months ago

Adicet Bio Proxy statement: Proxy Filing

Nov 11, 2025, 3:00 PM EST - 10 months ago

Adicet Bio Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 5, 2025, 4:01 PM EST - 10 months ago

Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 5, 2025, 7:00 AM EST - 10 months ago

Adicet Bio Earnings release: Q3 2025

Nov 5, 2025, 7:00 AM EST - 10 months ago

Adicet Bio Quarterly report: Q3 2025

Nov 5, 2025, 7:00 AM EST - 10 months ago

Adicet Bio Proxy statement: Proxy Filing

Oct 31, 2025, 4:59 PM EDT - 10 months ago

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Oct 28, 2025, 7:00 AM EDT - 10 months ago

Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

$Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)$

Oct 16, 2025, 7:00 AM EDT - 11 months ago

Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

Oct 7, 2025, 8:00 AM EDT - 11 months ago

Adicet Bio Transcript: Study Update

Oct 7, 2025, 8:00 AM EDT - 11 months ago

Adicet Bio Press release: Study Update

Oct 7, 2025, 8:00 AM EDT - 11 months ago

Adicet Bio Slides: Study Update

Oct 7, 2025, 7:01 AM EDT - 11 months ago

Adicet Bio, Inc. Announces $80 Million Registered Direct Offering

Oct 7, 2025, 6:45 AM EDT - 11 months ago

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Sep 8, 2025, 4:30 PM EDT - 1 year ago

Adicet Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 7:00 AM EDT - 1 year ago

Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 1:30 PM EDT - 1 year ago

Adicet Bio Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 7, 2025, 4:01 PM EDT - 1 year ago

Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 7, 2025, 7:00 AM EDT - 1 year ago

Adicet Bio Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 1 year ago

Adicet Bio Quarterly report: Q2 2025

Aug 5, 2025, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference

Jul 24, 2025, 7:00 AM EDT - 1 year ago

Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Jun 5, 2025, 7:00 AM EDT - 1 year ago

Adicet Bio Slides: Investor Presentation

Jun 4, 2025, 4:20 PM EDT - 1 year ago

Adicet Bio Transcript: Jefferies Global Healthcare Conference 2025

May 21, 2025, 4:00 PM EDT - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

May 7, 2025, 1:30 PM EDT - 1 year ago

Adicet Bio Transcript: The Citizens JMP Life Sciences Conference 2025

May 6, 2025, 4:01 PM EDT - 1 year ago

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

May 6, 2025, 4:00 PM EDT - 1 year ago

Adicet Bio Quarterly report: Q1 2025

May 6, 2025, 4:00 PM EDT - 1 year ago

Adicet Bio Earnings release: Q1 2025

Apr 30, 2025, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Adicet Bio Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Adicet Bio Proxy statement: Proxy Filing

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

Apr 17, 2025, 7:00 AM EDT - 1 year ago

Adicet Bio Appoints Michael Grissinger to the Board of Directors

Mar 31, 2025, 5:12 PM EDT - 1 year ago

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 6, 2025, 4:01 PM EST - 1 year ago

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

Mar 6, 2025, 3:00 PM EST - 1 year ago

Adicet Bio Annual report: Q4 2024

Mar 6, 2025, 3:00 PM EST - 1 year ago

Adicet Bio Earnings release: Q4 2024

Mar 6, 2025, 7:00 AM EST - 1 year ago

Adicet Bio Registration statement: Registration Filing

Mar 3, 2025, 7:00 AM EST - 1 year ago

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

Feb 27, 2025, 7:00 AM EST - 1 year ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

Feb 5, 2025, 2:00 PM EST - 1 year ago

Adicet Bio Transcript: Guggenheim SMID Cap Biotech Conference

$Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement$

Feb 5, 2025, 7:10 AM EST - 1 year ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

Jan 29, 2025, 7:00 AM EST - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Jan 8, 2025, 4:10 PM EST - 1 year ago

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

Dec 19, 2024, 7:00 AM EST - 1 year ago

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Dec 18, 2024, 7:00 AM EST - 1 year ago

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

Nov 19, 2024, 7:30 AM EST - 1 year ago

Adicet Bio Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 4:00 PM EST - 1 year ago

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Nov 18, 2024, 7:00 AM EST - 1 year ago

Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Nov 16, 2024, 9:00 AM EST - 1 year ago

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

Nov 12, 2024, 3:00 PM EST - 1 year ago

Adicet Bio Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 6, 2024, 4:00 PM EST - 1 year ago

Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 5, 2024, 6:00 PM EST - 1 year ago

Adicet Bio Quarterly report: Q3 2024

Nov 5, 2024, 6:00 PM EST - 1 year ago

Adicet Bio Earnings release: Q3 2024

Nov 5, 2024, 7:00 AM EST - 1 year ago

Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024

Nov 1, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in Upcoming Investor Conferences

Oct 16, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Sep 30, 2024, 4:30 PM EDT - 1 year ago

Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

Sep 19, 2024, 7:00 AM EDT - 1 year ago

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue

Sep 18, 2024, 8:00 PM EDT - 1 year ago

Adicet Bio Transcript: 9th Annual CAR-TCR U.S. Summit

Sep 18, 2024, 8:00 PM EDT - 1 year ago

Adicet Bio Slides: 9th Annual CAR-TCR U.S. Summit

Sep 10, 2024, 2:30 PM EDT - 2 years ago

Adicet Bio Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 27, 2024, 4:00 PM EDT - 2 years ago

Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 19, 2024, 7:00 AM EDT - 2 years ago

Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors

Aug 13, 2024, 10:30 AM EDT - 2 years ago

Adicet Bio Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Aug 13, 2024, 10:30 AM EDT - 2 years ago

Adicet Bio Slides: FY 2024

Aug 13, 2024, 7:00 AM EDT - 2 years ago

Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 13, 2024, 7:00 AM EDT - 2 years ago

Adicet Bio Quarterly report: Q2 2024

Aug 13, 2024, 7:00 AM EDT - 2 years ago

Adicet Bio Earnings release: Q2 2024

BiotechValues Sep. 15 at 8:04 PM

$ACET wants to show CRR of 40%+ at 12 months in LN population for a win

0 · Reply

BullyMCBullface Sep. 15 at 7:34 PM

$ACET 🙌🏻🙌🏻🙌🏻🙌🏻🙌🏻

0 · Reply

BiotechValues Sep. 15 at 7:26 PM

0 · Reply

THSSKS Sep. 15 at 6:07 PM

$ACET bought a small stake here. Don’t let me down

0 · Reply

thebrockettman Sep. 15 at 4:15 PM

0 · Reply

rml360 Sep. 15 at 3:59 PM

$ACET shit did the data leak?

0 · Reply

Peterson28 Sep. 15 at 3:39 PM

$ACET Stop loss hunting

0 · Reply

BioTechChap Sep. 15 at 3:10 PM

$ACET 2 weeks of gain wiped out in 2 hours. They better have a solid story during HCW Conference today

1 · Reply

glaucio Sep. 14 at 4:48 PM

$ACET you’re alive

0 · Reply

danielmaia12 Sep. 9 at 12:02 PM

$ACET Multiple cancer indications give the platform several shots on goal...

0 · Reply

DCZ Sep. 8 at 10:41 PM

$ACET

1 · Reply

Peterson28 Sep. 8 at 9:32 PM

$ACET Data is out but no market reaction.

2 · Reply

AGC_Trader Sep. 4 at 2:25 PM

$ACET Is this when they are going to release the data? https://www.businesswire.com/news/home/20260902301741/en/Adicet-Bio-to-Participate-in-Fireside-Chat-at-H.C.-Wainwright-28th-Annual-Global-Investment-Conference

2 · Reply

YouVSYou Sep. 3 at 1:51 AM

$ACET veey intriguing Bio name Here will be doing more dd $ONDS $HIMS $CLSK Extensive dd in the chat Link in bio

0 · Reply

BioTechChap Sep. 1 at 6:29 PM

$ACET It’s subtle, yet possibly quite bullish: today’s PR refers to SLE with or without LN. Over the last few months, the CEO repeatedly hinted at prioritising LN over SLE, with the latter as an expansion indication. Should they have a dataset with compelling results in both indications, there may be a possibility that they will proceed with a broad lupus, registrational trial in a community setting.

0 · Reply

DCZ Sep. 1 at 4:54 PM

$ACET based on the pr today, it sounds like they are setting up good news for this trial update. We also have an update in Systemic sclerosis in q4 and have more timeline details on the progress of their in vivo portfolio. This was a great pr, hence the sp rise today!

0 · Reply

BioTechChap Sep. 1 at 1:06 PM

$ACET Whatever the price action today, PR was good timing in light of CAR-T panic that broke out yesterday.

0 · Reply

rml360 Sep. 1 at 11:13 AM

$ACET looks like data not imminent end of the month

0 · Reply

focafoca99 Sep. 1 at 11:13 AM

$ACET shared that the last patient visit for its prula-cel lupus study has been completed, paving the way for data analysis.

0 · Reply

badInvestments67 Sep. 1 at 2:44 AM

$ACET you should all sell

0 · Reply

AGC_Trader Aug. 28 at 6:33 PM

$ACET Could have they decided a worse moment to announce the news? Probably not...

0 · Reply

elmono Aug. 27 at 9:38 PM

$ACET trash will be trash 😂😂

0 · Reply

Market Cap	90.81M
Revenue (ttm)	0.00
Net Income (ttm)	-116.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	479,200
Avg Vol	102,108
Day's Range	N/A - N/A
Shares Out	9.36M
Stochastic %K	29%
Beta	1.58
Analysts	Strong Sell
Price Target	$33.17